UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2346-1
Program Prior Authorization/Medical Necessity
Medication Duvyzat™ (givinostat) oral suspension
P&T Approval Date 7/2024
Effective Date 10/1/2024
1. Background:
Duvyzat (givinostat) is a histone deacetylase inhibitor indicated for the treatment of Duchenne
muscular dystrophy (DMD) in patients 6 years of age and older.
2. Coverage Criteriaa:
A. Initial Authorization
1. Duvyzat will be approved based upon all of the following criteria:
a. Diagnosis of Duchenne muscular dystrophy (DMD)
-AND-
b. Diagnosis confirmed by the presence of a mutation in the DMD gene
-AND-
c. Patient is 6 years of age or older
-AND-
d. Submission of medical records (e.g., chart notes) confirming that the patient is
ambulatory without needing an assistive device (e.g., without side-by-side assist,
cane, walker, wheelchair, etc.)
-AND-
e. Patient has been or will be established on a stable corticosteroid regimen
-AND-
f. Prescribed by, or in consultation with, a pediatric neuromuscular specialist with
expertise in the treatment of DMD
-AND-
g. Patient has not received gene therapy for DMD [e.g., Elevidys (delandistrogene
moxparvovec-rokl)]
-AND-
© 2024 UnitedHealthcare Services, Inc.
1
h. Patient will not receive Duvyzat in combination with exon-skipping therapies for
DMD [e.g., Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen),
Vyondys 53 (golodirsen)]
Authorization will be issued for 12 months.
B. Reauthorization
1. Duvyzat will be approved based on all the following criterion:
a. Physician attestation that patient would benefit from continued administration.
-AND-
b. Submission of medical records (e.g., chart notes) confirming that the patient is
ambulatory without needing an assistive device (e.g., without side-by-side assist,
cane, walker, wheelchair, etc.)
-AND-
c. Patient continues to receive concomitant corticosteroid regimen
-AND-
d. Prescribed by, or in consultation with, a pediatric neuromuscular specialist with
expertise in the treatment of DMD
-AND-
e. Patient has not received gene therapy for DMD [e.g., Elevidys (delandistrogene
moxparvovec-rokl)]
-AND-
f. Patient will not receive Duvyzat in combination with exon-skipping therapies for
DMD [e.g., Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen),
Vyondys 53 (golodirsen)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
© 2024 UnitedHealthcare Services, Inc.
2
4. Reference:
1. Duvyzat [package insert]. Concord, MA: ITF Therapeutics, LLC; March 2024.
2. Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al. Safety and efficacy of givinostat in boys with
Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-
controlled, phase 3 trial [published correction appears in Lancet Neurol. 2024 Jun;23(6):e10].
Lancet Neurol. 2024;23(4):393-403.
3. Gloss D, Moxley III R, Ashwal S, et. al. Practice guideline update summary: Corticosteroid
treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee
of the American Academy of Neurology. Neurology 2016; 86;465-472.
Program Prior Authorization/Medical Necessity - Duvyzat (givinostat)
Change Control
7/2024 New program.
© 2024 UnitedHealthcare Services, Inc.
3